@article{844c074f2971446494ae86bea513b5fb,
title = "Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance",
abstract = "The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and-intolerant patients with CML-CP (n=321) were treated with nilotinib 400 mg twice daily. Of 19 baseline patient and disease characteristics and two response end points analyzed, 10 independent prognostic factors were associated with progression-free survival (PFS). In the multivariate analysis, major cytogenetic response (MCyR) within 12 months, baseline hemoglobin ≥120 g/l, baseline basophils <4%, and absence of baseline mutations with low sensitivity to nilotinib were associated with PFS. A prognostic score was created to stratify patients into five groups (best group: 0 of 3 unfavorable risk factors and MCyR by 12 months; worst group: 3 of 3 unfavorable risk factors and no MCyR by 12 months). Estimated 24-month PFS rates were 90%, 79%, 67% and 37% for patients with prognostic scores of 0, 1, 2 and 3, respectively, (no patients with score of 4). Even in the presence of poor disease characteristics, nilotinib provided significant clinical benefit in patients with imatinib-resistant or-intolerant CML. This system may yield insight on the prognosis of patients.",
keywords = "chronic myeloid leukemia, imatinib intolerance, imatinib resistance, multivariate analysis, nilotinib, predictive model",
author = "E. Jabbour and {Le Coutre}, {P. D.} and J. Cortes and F. Giles and Bhalla, {K. N.} and J. Pinilla-Ibarz and Larson, {R. A.} and N. Gattermann and Ottmann, {O. G.} and A. Hochhaus and Hughes, {T. P.} and G. Saglio and Radich, {J. P.} and Kim, {D. W.} and G. Martinelli and J. Reynolds and Woodman, {R. C.} and M. Baccarani and Kantarjian, {H. M.}",
note = "Funding Information: EJ received honoraria from Novartis and BMS. PDlC acted as a consultant and received honoraria for Novartis and BMS and received research funding from Novartis. JEC acted as a consultant for Novartis, BMS and Pfizer and received research funding from Novartis, BMS, Pfizer, Ariad and Chemgenex. FJG acted as a consultant, received honoraria and research funding from Novartis. KNB received honoraria and research funding from Novartis. JP-I acted as a consultant for Novartis and BMS and received honoraria from Novartis. RAL acted as a consultant, received honoraria, and received research funding from Novartis. NG received honoraria and research funding from Novartis. OGO acted as a consultant, received honoraria, and research funding from Novartis. AH acted as a consultant for Novartis, BMS, Pfizer and Ariad, and received honoraria and research funding from Novartis, BMS and Pfizer. TPH acted as a consultant and received research funding from Novartis, BMS and Ariad. GS acted as a consultant for Novartis, BMS and Pfizer and received honoraria from BMS and Novartis. JPR acted as a consultant for Novartis, BMS, Ariad and Pfizer and received research funding from Novartis. D-WK received honoraria from Novartis and BMS and received research funding from Novartis, BMS, Pfizer and Ariad. GM acted as a consultant for Novartis, BMS, Pfizer and Genzyme, and received honoraria from Novartis and BMS; and research funding from Novartis. JR and RCW are Novartis employees and stock owners. MB acted as a consultant for Novartis, BMS and Pfizer, and received honoraria from Novartis, BMS and Pfizer, and received research funding from Novartis. HMK acted as a consultant for Novartis and received research funding from Novartis, BMS and Pfizer.",
year = "2013",
month = apr,
doi = "10.1038/leu.2012.305",
language = "English (US)",
volume = "27",
pages = "907--913",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",
}
